| Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center A Moens, D Alsoud, B Verstockt, J Sabino, M Ferrante, S Vermeire European Journal of Gastroenterology & Hepatology 34 (10), 1015-1020, 2022 | 9 | 2022 |
| Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology D Alsoud, DJAR Moes, Z Wang, R Soenen, Z Layegh, M Barclay, ... Therapeutic Drug Monitoring, 10.1097, 2022 | | 2022 |
| Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease D Alsoud, B Van Calster Inflammatory Bowel Diseases 30 (6), 1050-1051, 2024 | | 2024 |
| Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises D Alsoud, S Vermeire, B Verstockt Current Research in Pharmacology and Drug Discovery 3, 100089, 2022 | 12 | 2022 |
| Breaking the therapeutic ceiling in drug development in ulcerative colitis D Alsoud, B Verstockt, C Fiocchi, S Vermeire Lancet Gastroenterology & Hepatology 6 (7), S89-S95, 2021 | | 2021 |
| Breaking the therapeutic ceiling in drug development in ulcerative colitis D Alsoud, B Verstockt, C Fiocchi, S Vermeire The lancet Gastroenterology & hepatology 6 (7), 589-595, 2021 | 87 | 2021 |
| Comparative Effectiveness Research to Position Therapies in Ulcerative Colitis: How Fair Are the Comparisons? D Alsoud, B Verstockt, S Vermeire Clinical Gastroenterology and Hepatology 21 (5), 1372-1373, 2023 | | 2023 |
| DOP08 Serum proteomics predict endoscopic remission in patients with Crohn’s Disease D Alsoud, P Sudhakar, J Sabino, M Ferrante, B Verstockt, S Vermeire Journal of Crohn's and Colitis 15 (Supplement_1), S046-S047, 2021 | | 2021 |
| Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease D Alsoud, S Verstockt, J Sabino, M Ferrante, N Noor, B Verstockt, ... Journal Of Crohns & Colitis 15, S168-S168, 2021 | 4 | 2021 |
| Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn … N Van den Berghe, D Alsoud, B Verstockt, S Vermeire, P Declerck, ... Therapeutic Advances in Gastroenterology 16, 17562848231189110, 2023 | | 2023 |
| immunogenicity is not the root cause for loss of response to anti‐TNF agents in patients with IBD in TDM era. D Alsoud, B Verstockt, S Vermeire Alimentary Pharmacology & Therapeutics 55 (7), 2022 | 5 | 2022 |
| Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis B Verstockt, V Volk, C Jaeckel, D Alsoud, J Sabino, S Nikolaus, A Outtier, ... Alimentary Pharmacology & Therapeutics 56 (2), 282-291, 2022 | 8 | 2022 |
| Mo1558: REAL-WORLD EFFECTIVENESS AND SAFETY OF RISANKIZUMAB FOR MODERATE-SEVERE MULTI-REFRACTORY CROHN’S DISEASE: RESULTS FROM A BELGIAN MULTI-CENTRIC COHORT D Alsoud, D Franchimont, F D’Heygere, P Bossuyt, A Vijverman, ... Gastroenterology 162 (7), S-818-S-819, 2022 | | 2022 |
| Mo1560: USTEKINUMAB EFFECTIVENESS, DRUG PERSISTENCE AND SERUM EXPOSURE IN CROHN’S DISEASE ARE AFFECTED BY ITS POSITIONING D Alsoud, J Sabino, M Ferrante, S Vermeire, B Verstockt Gastroenterology 162 (7), S-819-S-820, 2022 | | 2022 |
| Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope? D Alsoud, S Vermeire, B Verstockt Current opinion in pharmacology 55, 17-30, 2020 | 31 | 2020 |
| P257 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn’s disease D Alsoud, J Sabino, M Ferrante, B Verstockt, S Vermeire Journal of Crohn's and Colitis 16 (Supplement_1), i298-i299, 2022 | | 2022 |
| P309 Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD A Moens, B Verstockt, D Alsoud, J Sabino, M Ferrante, S Vermeire Journal of Crohn's and Colitis 15 (Supplement_1), S336-S337, 2021 | | 2021 |
| P385 A mucosal marker predicting tofacitinib induced an endoscopic response in ulcerative colitis B Verstockt, S Verstockt, D Alsaoud, J Sabino, M Ferrante, S Vermeire Journal of Crohn's and Colitis 14 (Supplement_1), S358-S359, 2020 | 3 | 2020 |
| P401 Tofacitinib tissue exposure correlates with endoscopic outcome B Verstockt, D Alsoud, J van Oostrom, J Smith, J Stylli, S Singh, ... Journal of Crohn's and Colitis 16 (Supplement_1), i394-i395, 2022 | 4 | 2022 |
| P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn’s disease A Moens, B Verstockt, D Alsoud, J Sabino, M Ferrante, S Vermeire Journal of Crohn's and Colitis 16 (Supplement_1), i423-i424, 2022 | | 2022 |
